18486984

Source:http://linkedlifedata.com/resource/pubmed/id/18486984

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003451, umls-concept:C0019196, umls-concept:C0030705, umls-concept:C0035525, umls-concept:C0036043, umls-concept:C0391001, umls-concept:C0439228, umls-concept:C1280500, umls-concept:C1876229
pubmed:issue	2
pubmed:dateCreated	2008-7-8
pubmed:abstractText	This study assessed the safety and antiviral effects of telaprevir (VX-950) in combination with peginterferon alfa-2a and ribavirin.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8503886
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Alanine Transaminase, http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents, http://linkedlifedata.com/resource/pubmed/chemical/Aspartate Aminotransferases, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Oligopeptides, http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2a, http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2a, http://linkedlifedata.com/resource/pubmed/chemical/telaprevir
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	0168-8278
pubmed:author	pubmed-author:KhunvichaiAriyaA, pubmed-author:KiefferTara LTL, pubmed-author:LawitzEricE, pubmed-author:McHutchisonJohn GJG, pubmed-author:McNairLindsayL, pubmed-author:MuirAndrew JAJ, pubmed-author:Rodriguez-TorresMaribelM
pubmed:issnType	Print
pubmed:volume	49
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	163-9
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:18486984-Adult, pubmed-meshheading:18486984-Alanine Transaminase, pubmed-meshheading:18486984-Antiviral Agents, pubmed-meshheading:18486984-Aspartate Aminotransferases, pubmed-meshheading:18486984-Drug Therapy, Combination, pubmed-meshheading:18486984-Female, pubmed-meshheading:18486984-Hepacivirus, pubmed-meshheading:18486984-Hepatitis C, Chronic, pubmed-meshheading:18486984-Humans, pubmed-meshheading:18486984-Interferon-alpha, pubmed-meshheading:18486984-Male, pubmed-meshheading:18486984-Middle Aged, pubmed-meshheading:18486984-Oligopeptides, pubmed-meshheading:18486984-Polyethylene Glycols, pubmed-meshheading:18486984-RNA, Viral, pubmed-meshheading:18486984-Recombinant Proteins, pubmed-meshheading:18486984-Ribavirin, pubmed-meshheading:18486984-Treatment Outcome
pubmed:year	2008
pubmed:articleTitle	Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
pubmed:affiliation	Alamo Medical Research, 621 Camden Suite 202, San Antonio, TX 78215, USA. lawitz@alamomedicalresearch.com
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't